Review article: A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 8, 2001, Pages 1087-1100

  Souza, R F ^a,c   Morales, C P ^a   Spechler, S J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MC# 111B1 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; GROWTH FACTOR; RAS PROTEIN; SMAD PROTEIN;

APOPTOSIS; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL CYCLE; ESOPHAGEAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS;

EID: 0034923764     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01046.x     Document Type: Review

References (155)

1. Cancer statistics
2. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
3. A restriction point for control of normal animal cell proliferation
4. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization
5. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus
6. Mucosal polyamine metabolism in the columnar lined oesophagus
7. Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus
8. Ornithine decarboxylase activity in Barrett's esophagus: A potential marker for dysplasia
9. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model
10. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
11. Control of the cell cycle and apoptosis
12. The retinoblastoma protein and cell cycle control
13. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach
14. Increased expression of the cyclin D1 gene in Barrett's esophagus
15. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus
16. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon
17. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers
18. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas
19. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma
20. The complexity of p53 modulation: Emerging patterns from divergent signals
21. Participation of p53 protein in the cellular response to DNA damage
22. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry
23. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study
24. Overexpression of p53 protein in Barrett's syndrome with malignant transformation
25. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus
26. p53 and p21 (WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction
27. Analysis of Ki-67, 53 and Bcl-2 expression in the dysplasia - Carcinoma sequence of Barrett's esophagus
28. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma
29. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction
30. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma
31. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
32. Evolution of neoplastic cell lineages in Barrett oesophagus
33. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma
34. 17p (p53) allelic losses: 4N(G:2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus
35. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia
36. p53 gene mutations in Barrett's epithelium and esophageal cancer
37. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells
38. Induction of cyclin D1 overexpression by activated ras
39. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: A putative model for carcinogenesis
40. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma
41. Abnormal expression of growth regulatory factors in Barrett's oesophagus
42. Association of transforming growth factor alpha (TGFα) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables
43. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: Correlation with prognosis
44. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
45. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus
46. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations
47. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
48. RAS pathways to cell cycle control and cell transformation
49. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
50. Cellular transforming genes
51. Use of transfection to analyze genetic information and malignant transformation
52. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products
53. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas
54. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus
55. Role of transforming growth factor beta in human disease
56. Going mad with Smads
57. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
58. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-betal) type I and type II receptors in human prostate cancer
59. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
60. SMAD genes in juvenile polyposis
61. Somatic alterations of the SMAD-2 gene in human colorectal cancers
62. Frequency of Smad gene mutations in human cancers
63. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
64. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
65. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms
66. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
67. Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer
68. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma
69. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
70. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
71. A cell cycle regulator potentially involved in genesis of many tumor types
72. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
73. Cancer cell cycles
74. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
75. Allelotype analysis of esophageal adenocarcinomas: Evidence for the involvement of sequences on the long arm of chromosome 4
76. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms
77. Allelotype analysis of oesophageal adenocarcinoma: Loss of heterozygosity occurs at multiple sites
78. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas
79. The MTS1 gene is frequently mutated in primary human esophageal tumors
80. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers
81. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MT81 in human cancers
82. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
83. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
84. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
85. Cadherin-catenin complex: Protein interactions and their implications for cadherin function
86. Cadherins catenins and APC protein: Interplay between cytoskeletal complexes and signaling pathways
87. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts
88. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene
89. Beta-catenin mediates the interaction of the cadherin - Catenin complex with epidermal growth factor receptor
90. c-erbB-2 gene product associates with catenins in human cancer cells
91. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells
92. The E-cadherin/catenin complex in invasion and metastasis
93. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1
94. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3
95. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly
96. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton
97. The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin
98. Mutations in the APC gene and their implications for protein structure and function
99. Lessons from hereditary colorectal cancer
100. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
101. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma
102. Activation of betacatenin-Tcf signaling in colon cancer by mutations in betacatenin or APC
103. Stabilization of beta-catenin by genetic defects in melanoma cell lines
104. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: An immunohistochemical and immunoblot study
105. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas
106. Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus
107. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation
108. Gene mutations in the mutation cluster region are rare in esophageal cancers
109. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
110. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
111. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
112. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
113. Profile of gene expression regulated by induced p53: Connection to the TGF-beta family
114. Regulation of Lef-mediated transcription and p53-dependent pathway by associating β-catenin with CBP/p300
115. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
116. Identification of a phorbol ester-repressible v-src-inducible gene
117. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
118. Elevated cyclooxygenase-2 levels in Min mous adenomas
119. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
120. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2) -selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
121. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
122. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-June N-terminal kinase and p38 mitogen-activated protein kinase pathways
123. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
124. Aspirin use and risk of fatal cancer
125. Aspirin, NSAIDS, and colon cancer prevention: Mechanisms?
126. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group
127. Aspirin and the risk of colorectal cancer in women
128. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
129. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
130. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
131. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
132. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
133. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
134. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
135. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
136. Cyclooxygenase-2 expression in human esophageal carcinoma
137. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
138. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
139. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression
140. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
141. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor
142. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
143. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
144. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
145. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
146. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma
147. The host-tumor immune conflict: From immunosuppression to resistance and destruction
148. Fas-ligand: Privilege and peril
149. The role of FasL-induced apoptosis in immune privilege
150. Fas ligand and immune evasion
151. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
152. Fas ligand expression in esophageal carcinomas and their lymph node metastases
153. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus
154. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence
155. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma